MVRIX

MVRIX is a private South Korean biotechnology company founded in 2021 that develops platform-based therapeutics spanning targeted mRNA delivery, in vivo CAR-T, recombinant botulinum toxin, and virucidal antivirals. Its lead platform, Navibody, is an antibody-guided mRNA-lipid nanoparticle delivery technology designed to improve cell-specific targeting and enable in vivo gene and cell therapy applications. The company highlights MIC-001, an in vivo CAR-T program that targets CD3-positive T cells using mRNA@LNP delivery, and MBT-002, a recombinant botulinum toxin candidate that was licensed to Eyegene in 2025. MVRIX also lists early antiviral programs for COVID-19, influenza, avian influenza, and severe fever with thrombocytopenia syndrome. The business appears to be research-platform driven, with active collaborations across companies, universities, research institutes, and public-sector programs in Korea and the United States.